Value Partners Investments Inc. Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

Value Partners Investments Inc. lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 47.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,425 shares of the medical research company’s stock after selling 4,912 shares during the quarter. Value Partners Investments Inc.’s holdings in Thermo Fisher Scientific were worth $2,716,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of TMO. Keudell Morrison Wealth Management grew its stake in Thermo Fisher Scientific by 5.1% during the 2nd quarter. Keudell Morrison Wealth Management now owns 498 shares of the medical research company’s stock valued at $250,000 after purchasing an additional 24 shares in the last quarter. Firethorn Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 6.3% in the 2nd quarter. Firethorn Wealth Partners LLC now owns 526 shares of the medical research company’s stock valued at $264,000 after purchasing an additional 31 shares in the last quarter. Tectonic Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 5.5% during the 2nd quarter. Tectonic Advisors LLC now owns 1,869 shares of the medical research company’s stock valued at $937,000 after buying an additional 97 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of Thermo Fisher Scientific by 3.4% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 93,673 shares of the medical research company’s stock worth $46,964,000 after buying an additional 3,098 shares in the last quarter. Finally, Salem Investment Counselors Inc. increased its stake in shares of Thermo Fisher Scientific by 2.4% in the second quarter. Salem Investment Counselors Inc. now owns 17,376 shares of the medical research company’s stock worth $8,714,000 after buying an additional 414 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on TMO. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. Finally, Robert W. Baird cut their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Trading Down 1.3%

Shares of NYSE TMO opened at $588.17 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99. The company has a market cap of $217.48 billion, a price-to-earnings ratio of 31.64, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The stock’s 50 day simple moving average is $529.37 and its 200 day simple moving average is $509.58.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Insider Activity

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 52,053 shares of company stock worth $30,643,589 over the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.